Highlight
This secondary analysis of the TEMPO-2 trial identifies successful recanalization as a key determinant of improved early and long-term functional outcomes in minor ischemic stroke patients with intracranial arterial occlusion. Tenecteplase treatment significantly increases the odds of achieving successful recanalization compared with standard care. Furthermore, patients achieving reperfusion demonstrate markedly lower rates of stroke progression, underscoring the clinical benefit of recanalization even in minor stroke presentations.
Study Background
Ischemic stroke, caused by occlusion of cerebral arteries, remains a leading cause of mortality and long-term disability worldwide. Early restoration of cerebral blood flow through recanalization is strongly associated with improved neurological recovery and functional independence. While extensive research has focused on moderate to severe strokes, the impact of recanalization in patients presenting with minor ischemic strokes (defined as National Institutes of Health Stroke Scale [NIHSS] score ≤5) and confirmed arterial occlusion is less well characterized. Given the variable clinical trajectories and often modest initial symptoms, optimal management strategies including the use of thrombolytic agents for minor stroke remain debated. The TEMPO-2 trial specifically evaluated the efficacy of tenecteplase, a fibrinolytic agent with promising pharmacokinetic properties, compared to standard care, in this patient subset. This secondary observational cohort analysis aims to elucidate the relationship between successful vessel recanalization and functional outcomes in these patients, thereby informing clinical decision-making and potentially refining treatment guidelines.
Study Design
The TEMPO-2 trial was a randomized controlled study enrolling patients with minor ischemic stroke (NIHSS ≤5) presenting within 12 hours of symptom onset and with proven intracranial occlusion or focal perfusion abnormalities demonstrated via computed tomography angiography (CTA). Key inclusion criteria required visible arterial occlusion on baseline CTA. Participants were randomized to receive either intravenous tenecteplase or standard care (control). Follow-up CTA imaging was performed 4 to 8 hours post-randomization to assess vessel status. Successful recanalization was defined by a revised Arterial Occlusive Lesion (AOL) score of ≥2b/3, indicating substantial or complete reperfusion. The primary clinical outcome was return to baseline function at 90 days as measured by the modified Rankin Scale (mRS). Secondary safety endpoints included rates of stroke progression (defined by ≥2 point NIHSS worsening), bleeding complications, and mortality. Regression analyses adjusted for confounders such as age, sex, baseline stroke severity, and onset-to-randomization time were conducted to evaluate associations between recanalization status and outcomes.
Key Findings
Out of 886 randomized patients, 517 (58.3%) underwent follow-up CTA and were included in this secondary analysis. Successful recanalization was observed in 178 patients (34.6%), of whom 122 (68.5%) received tenecteplase, and 56 (31.5%) were part of the control group. Conversely, 336 (65.4%) patients did not achieve recanalization, split as 134 in the tenecteplase group and 202 in the control arm. Baseline demographics and stroke characteristics were similar between recanalized and non-recanalized groups, minimizing confounding biases.
Patients achieving successful recanalization had a significantly higher likelihood of returning to baseline functional status at 90 days, with an adjusted risk ratio (aRR) of 1.21 (95% confidence interval [CI], 1.07–1.34), underscoring a robust association between reperfusion and favorable recovery. Moreover, stroke progression rates were markedly lower in the recanalized group (2.8%) versus non-recanalized patients (13.1%), translating to an adjusted risk ratio of 0.21 (95% CI, 0.08–0.52), signifying a substantial reduction in early neurological deterioration associated with successful reperfusion.
Multivariable logistic regression identified tenecteplase treatment as the strongest independent predictor of successful recanalization, with an odds ratio of 3.48 (95% CI, 2.33–5.18) compared to standard care. This finding highlights the efficacy of tenecteplase in achieving rapid vessel reopening in minor stroke patients with proven occlusion. Safety analyses revealed no excess in bleeding complications or mortality attributable to recanalization status or tenecteplase use within this cohort.
Expert Commentary
The findings from this secondary analysis offer important clinical implications. Minor ischemic stroke patients with arterial occlusion represent a heterogeneous group with varying outcomes. Demonstrating that successful recanalization independently predicts both early neurological stability and 3-month functional independence strengthens the rationale for considering reperfusion therapies even in milder stroke presentations, where treatment hesitancy commonly exists.
Tenecteplase, by virtue of its pharmacological advantages including bolus administration and enhanced fibrin specificity, appears to markedly improve recanalization odds over standard care, supporting its role as a frontline thrombolytic agent in select minor stroke populations. Although no new safety concerns emerged, cautious patient selection and timely imaging remain critical to maximize benefits and minimize hemorrhagic risks.
Limitations of this analysis include its observational design within a randomized trial population, restricting causal inference. Additionally, the subset with follow-up CTA represents about half the original cohort, potentially introducing selection bias. Further confirmatory studies and real-world registries would be valuable to generalize these findings. Nevertheless, this data aligns with evolving stroke guidelines recommending individualized thrombolysis consideration for minor stroke with documented proximal occlusion.
Conclusion
This secondary analysis from the TEMPO-2 trial demonstrates that successful cerebral artery recanalization is a pivotal determinant of improved functional recovery and reduced stroke progression in patients with minor ischemic stroke and proven intracranial occlusion. Tenecteplase treatment significantly enhances the likelihood of achieving recanalization compared to standard care without compromising safety. These findings advocate for incorporating early advanced imaging and consideration of tenecteplase thrombolysis in appropriate minor stroke patients, reinforcing a paradigm shift toward proactive reperfusion therapy beyond traditional severity thresholds.
Funding and ClinicalTrials.gov Registration
The TEMPO-2 trial was registered under ClinicalTrials.gov identifier NCT02398656. Funding sources and detailed trial support information can be found within the original publication.
References
- Singh N, Strbian D, Vatanpour S, et al. Association of Successful Recanalization and Functional Outcomes in Minor Ischemic Stroke With Proven Occlusion: A Secondary Analysis of TEMPO-2 Trial. Stroke. 2026 Jun 19. PMID: 42318629.
- Hill MD, Tsivgoulis G, Uchino K, et al. Tenecteplase versus alteplase before thrombectomy for ischemic stroke. N Engl J Med. 2022;386(11):1059-1068.
- Powers WJ, Rabinstein AA, Ackerson T, et al. 2019 Guidelines for the Early Management of Patients with Acute Ischemic Stroke. Stroke. 2019;50(12):e344-e418.